HomeComparePSCE vs MRK

PSCE vs MRK: Dividend Comparison 2026

PSCE yields 1.83% · MRK yields 2.81%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 MRK wins by $35.4K in total portfolio value
10 years
PSCE
PSCE
● Live price
1.83%
Share price
$60.97
Annual div
$1.12
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$22.4K
Annual income
$206.38
Full PSCE calculator →
MRK
Merck & Co. Inc.
● Live price
2.81%
Share price
$118.10
Annual div
$3.32
5Y div CAGR
32.7%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$57.7K
Annual income
$10,113.78
Full MRK calculator →

Portfolio growth — PSCE vs MRK

📍 MRK pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodPSCEMRK
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, PSCE + MRK cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
PSCE pays
MRK pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

PSCE
Annual income on $10K today (after 15% tax)
$155.80/yr
After 10yr DRIP, annual income (after tax)
$175.42/yr
MRK
Annual income on $10K today (after 15% tax)
$238.95/yr
After 10yr DRIP, annual income (after tax)
$8,596.71/yr
At 15% tax rate, MRK beats the other by $8,421.29/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of PSCE + MRK for your $10,000?

PSCE: 50%MRK: 50%
100% MRK50/50100% PSCE
Portfolio after 10yr
$40.0K
Annual income
$5,160.08/yr
Blended yield
12.89%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on MRK right now

PSCE
No analyst data
MRK
Analyst Ratings
24
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$128.54
+8.8% upside vs current
Range: $100.00 — $150.00
Altman Z
4.0
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

PSCE buys
0
MRK buys
8
PoliticianChamberTickerTypeAmountDate
Josh Gottheimer🏢 House$MRK▲ Buy$1,001 - $15,0002026-02-04
Michael McCaul🏢 House$MRK▼ Sell$15,001 - $50,0002026-01-13
Gilbert Cisneros🏢 House$MRK▲ Buy$1,001 - $15,0002025-12-19
Julie Johnson🏢 House$MRK▼ Sell$1,001 - $15,0002025-12-18
Julie Johnson🏢 House$MRK▼ Sell$1,001 - $15,0002025-11-13
Ro Khanna🏢 House$MRK▼ Sell$1,001 - $15,0002025-09-29
Val Hoyle🏢 House$MRK▼ Sell$1,001 - $15,0002025-09-23
Marjorie Taylor Greene🏢 House$MRK▲ Buy$1,001 - $15,0002025-08-28
Julie Johnson🏢 House$MRK▼ Sell$1,001 - $15,0002025-08-14
Gilbert Cisneros🏢 House$MRK▲ Buy$1,001 - $15,0002025-08-05
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricPSCEMRK
Forward yield1.83%2.81%
Annual dividend / share$1.12$3.32
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%32.7%
Portfolio after 10y$22.4K$57.7K
Annual income after 10y$206.38$10,113.78
Total dividends collected$2.0K$29.8K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: PSCE vs MRK ($10,000, DRIP)

YearPSCE PortfolioPSCE Income/yrMRK PortfolioMRK Income/yrGap
1← crossover$10,883$183.30$11,213$373.04$330.00MRK
2$11,832$186.44$12,667$512.06$835.00MRK
3$12,849$189.42$14,439$708.14$1.6KMRK
4$13,941$192.26$16,640$988.16$2.7KMRK
5$15,112$194.95$19,432$1,394.07$4.3KMRK
6$16,367$197.49$23,057$1,992.90$6.7KMRK
7$17,713$199.91$27,889$2,894.79$10.2KMRK
8$19,155$202.19$34,518$4,286.29$15.4KMRK
9$20,700$204.34$43,912$6,494.35$23.2KMRK
10$22,355$206.38$57,714$10,113.78$35.4KMRK

PSCE vs MRK: Complete Analysis 2026

PSCEStock

The Invesco S&P SmallCap Energy ETF (Fund) is based on the S&P SmallCap 600 Capped Energy Index (Index). The Fund will normally invest at least 90% of its total assets in the securities of small-capitalization US energy companies that comprise the Underlying Index. The Index is designed to measure the overall performance of common stocks of US energy companies. These companies are principally engaged in the business of producing, distributing or servicing energy related products, including oil and gas exploration and production, refining, oil services and pipelines.The Index is a subset of the S&P SmallCap 600 Index, which is a float-adjusted, market-capitalization-weighted index reflecting the US small-cap market. The Fund and the Index are rebalanced and reconstituted quarterly.Effective at the close of markets on July 14, 2023, the Fund will effect a “1 for 5” reverse split of its issued and outstanding shares. The Fund’s CUSIP also changed from 46138E164 to 46138G474. Please see the prospectus for more information.

Full PSCE Calculator →

MRKHealthcare

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.

Full MRK Calculator →
📬

Get this PSCE vs MRK comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

PSCE vs SCHDPSCE vs JEPIPSCE vs OPSCE vs KOPSCE vs MAINPSCE vs JNJPSCE vs ABBVPSCE vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.